Clinical Trials Browser

Diabetes Mellitus, Carcinoma, Hepatocellular

Lymphoma, Non-Hodgkin, Recurrence

Esophageal Neoplasms

Cholangiocarcinoma

Colorectal Neoplasms, Neoplasm, Residual

Nasopharyngeal Carcinoma

Carcinoma, Non-Small-Cell Lung

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

Carcinoma, Hepatocellular

Squamous Cell Carcinoma of Head and Neck

Bile Duct Neoplasms, Biliary Tract Neoplasms, Cholangiocarcinoma, Klatskin Tumor

Rectal Neoplasms

Unresectable Stage III Non-small Cell Lung Cancer

Colorectal Neoplasms

Small Cell Lung Carcinoma

Lymphatic Metastasis

Carcinoma, Hepatocellular

Carcinoma, Hepatocellular

Carcinoma, Non-Small-Cell Lung

Carcinoma, Hepatocellular

Patients With Initially Unresectable MSS-type Advanced Colorectal Cancer With Liver and/or Lung and Peritoneal Metastasis

Colorectal Neoplasms

Recurrence, Lymphoma, Extranodal NK-T-Cell

Gastrointestinal Neoplasms, Pancreatic Neoplasms

Skin Neoplasms

Small Cell Lung Carcinoma

Carcinoma, Hepatocellular

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Hodgkin Disease

Pathologic Complete Response, Rectal Neoplasms

Clinical Trials

Epalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and Diabetes

A Study of CD19/22 CART Cells Combined With PD-1 Inhibitor in Relapsed/Refractory B-cell Lymphoma

MRD2START

Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Combined With Tislelizumab and Regorafenib as First-Line Therapy for Advanced Cholangiocarcinoma

SITISVEAL

A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma

Hypofractionated Chemoradiotherapy With Tislelizumab and Surufatinib for Unresectable Stage III NSCLC

Nimotuzumab Combined With PD-1 Inhibitors and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma

Tislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular Carcinoma

A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients.

Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky Tumors

Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma

TNTIT

BEACON-Lung

TRIUNITE06

Tislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLC

Propranolol With Tislelizumab Plus GC in Neoadjuvant Bladder UC

Phase II Study of Moderate-dose Hypofractionated RT Combined With Tislelizumab for HCC With Diffuse Tumor Thrombosis

A Clinical Trial of Firsekibart, Tislelizumab, and Lenvatinib in Patients With Unresectable, TP53-Mutated Hepatocellular Carcinoma

Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure

Neoadjuvant Tislelizumab-Lenvatinib vs Surgery Alone in Stage Ia HCC With Narrow Margin

Modified Short-Course Radiotherapy Combined With Immunochemotherapy and Targeted Therapy as First-Line Treatment for MSS Metastatic Colorectal Cancer

LDRT Combined With Immunochemotherapy for Colorectal Cancer With Liver Metastasis

EpiRev-NKT

A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer

Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy

A Prospective, Multicenter Exploratory Clinical Study on Consolidation Therapy With Tislelizumab Combined With Nintedanib for Limited-stage Small Cell Lung Cancer

A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence

Study to Evaluate the Efficacy and Safety of Adjuvant Tislelizumab in High-Risk Stage I NSCLC

HOVON164HL

Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer（CONTROL-01）